Your browser doesn't support javascript.
loading
Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III.
Jauze, Louisa; Monteillet, Laure; Mithieux, Gilles; Rajas, Fabienne; Ronzitti, Giuseppe.
Afiliación
  • Jauze L; INTEGRARE, Genethon, Inserm, Université d'Evry, Université Paris-Saclay, Evry, France.
  • Monteillet L; Institut National de la Santé et de la Recherche Médicale, U1213, Lyon, France.
  • Mithieux G; Université de Lyon, Lyon, France.
  • Rajas F; Université Lyon I, Villeurbanne, France.
  • Ronzitti G; Institut National de la Santé et de la Recherche Médicale, U1213, Lyon, France.
Hum Gene Ther ; 30(10): 1263-1273, 2019 10.
Article en En | MEDLINE | ID: mdl-31319709
Glycogen storage diseases (GSDs) type I (GSDI) and type III (GSDIII), the most frequent hepatic GSDs, are due to defects in glycogen metabolism, mainly in the liver. In addition to hypoglycemia and liver pathology, renal, myeloid, or muscle complications affect GSDI and GSDIII patients. Currently, patient management is based on dietary treatment preventing severe hypoglycemia and increasing the lifespan of patients. However, most of the patients develop long-term pathologies. In the past years, gene therapy for GSDI has generated proof of concept for hepatic GSDs. This resulted in a recent clinical trial of adeno-associated virus (AAV)-based gene replacement for GSDIa. However, the current limitations of AAV-mediated gene transfer still represent a challenge for successful gene therapy in GSDI and GSDIII. Indeed, transgene loss over time was observed in GSDI liver, possibly due to the degeneration of hepatocytes underlying the physiopathology of both GSDI and GSDIII and leading to hepatic tumor development. Moreover, multitissue targeting requires high vector doses to target nonpermissive tissues such as muscle and kidney. Interestingly, recent pharmacological interventions or dietary regimen aiming at the amelioration of the hepatocyte abnormalities before the administration of gene therapy demonstrated improved efficacy in GSDs. In this review, we describe the advances in gene therapy and the limitations to be overcome to achieve efficient and safe gene transfer in GSDs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Genética / Enfermedad del Almacenamiento de Glucógeno Tipo I / Enfermedad del Almacenamiento de Glucógeno Tipo III / Dependovirus / Glucosa-6-Fosfatasa / Hipoglucemia Límite: Animals / Humans Idioma: En Revista: Hum Gene Ther Asunto de la revista: GENETICA MEDICA / TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Genética / Enfermedad del Almacenamiento de Glucógeno Tipo I / Enfermedad del Almacenamiento de Glucógeno Tipo III / Dependovirus / Glucosa-6-Fosfatasa / Hipoglucemia Límite: Animals / Humans Idioma: En Revista: Hum Gene Ther Asunto de la revista: GENETICA MEDICA / TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos